Cardiac toxicity associated with HCV direct antiviral agents Heart in HCV DAAs therapy
Main Article Content
Keywords
Heart, arrhythmias, DAAs, adverse events, HCV
Downloads
Download data is not yet available.
Abstract 1122
PDF Downloads 752
HTML Downloads 107
References
1. Ucciferri C, Mancino P, Vignale F, Vecchiet J, Falasca K. Induction with ribavirin in a relapsing patient with chronic HCV hepatitis. Braz J Infect Dis 2012;16(3):297-9.https://doi.org/10.1016/S1413-8670(12)70328-82.
2. Maan R, van Tilborg M, Deterding K, Ramji A, van der Meer AJ, Wong F, Fung S, Sherman M, Manns MP, Cornberg M, Hansen BE, Wedemeyer H, Janssen HL, de Knegt RJ, Feld JJ. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. Clin GastroenterolHepatol.2016Dec;14(12):1821-1830.e6. doi:10.1016/j.cgh.2016.07.001.https://doi.org/10.1016/j.cgh.2016.07.0013.
3. Mancino P, Falasca K, Ucciferri C, Pizzigallo E, Vecchiet J. Use of hematopoietic growth factor in the management of hematological side effects associated to antiviral treatment for HCV hepatitis. Mediterr J HematolInfectDis2010;21):e2010003.https://doi.org/10.4084/mjhid.2010.0034.
4. Dahal,S.,Upadhyay,S.,Banjade,R.,Dhakal,P.,Khanal,N.,&Bhatt,V. R. (2017). Thrombocytopenia in patients with chronic hepatitis c virus infection. Mediterranean Journal of Hematology and Infectious Diseases, 2017, 9(1), e2017019.https://doi.org/10.4084/mjhid.2017.0195.
5. Back DJ, Burger DM. Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: potential mechanisms and lessons to be learned. Gastroenterology 2015;149(6):1315-7https://doi.org/10.1053/j.gastro.2015.09.031PMid:264163286.
6. Lagrutta A, Zeng H, Imredy J, Balasubramanian B, Dech S, Lis E, et al. Interaction between amiodarone and hepatitis-C virus nucleotide inhibitors in human induced pluripotent stem cell-derived cardiomyocytes and HEK-293 Cav1.2 over-expressing cells. Toxicol Appl Pharmacol 2016;308:66-76.https://doi.org/10.1016/j.taap.2016.08.006PMid:275207587.
7. Renet S, Chaumais MC, Antonini T, Zhao A, Thomas L, Savoure A, et al. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. Gastroenterology 2015;149(6):1378-80e1.8.
8. Ahmad T, Yin P, Saffitz J, Pockros PJ, Lalezari J, Shiffman M, et al. Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. Hepatology 2015;62(2):409-16.https://doi.org/10.1002/hep.27488PMid:252511569.
9. Zahno A, Brecht K, Morand R, Maseneni S, Torok M, Lindinger PW, et al. The role of CYP3A4 in amiodarone-associated toxicity on HepG2 cells. Biochem Pharmacol 2011;81(3):432-41.https://doi.org/10.1016/j.bcp.2010.11.002PMid:21070748
.
2. Maan R, van Tilborg M, Deterding K, Ramji A, van der Meer AJ, Wong F, Fung S, Sherman M, Manns MP, Cornberg M, Hansen BE, Wedemeyer H, Janssen HL, de Knegt RJ, Feld JJ. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. Clin GastroenterolHepatol.2016Dec;14(12):1821-1830.e6. doi:10.1016/j.cgh.2016.07.001.https://doi.org/10.1016/j.cgh.2016.07.0013.
3. Mancino P, Falasca K, Ucciferri C, Pizzigallo E, Vecchiet J. Use of hematopoietic growth factor in the management of hematological side effects associated to antiviral treatment for HCV hepatitis. Mediterr J HematolInfectDis2010;21):e2010003.https://doi.org/10.4084/mjhid.2010.0034.
4. Dahal,S.,Upadhyay,S.,Banjade,R.,Dhakal,P.,Khanal,N.,&Bhatt,V. R. (2017). Thrombocytopenia in patients with chronic hepatitis c virus infection. Mediterranean Journal of Hematology and Infectious Diseases, 2017, 9(1), e2017019.https://doi.org/10.4084/mjhid.2017.0195.
5. Back DJ, Burger DM. Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: potential mechanisms and lessons to be learned. Gastroenterology 2015;149(6):1315-7https://doi.org/10.1053/j.gastro.2015.09.031PMid:264163286.
6. Lagrutta A, Zeng H, Imredy J, Balasubramanian B, Dech S, Lis E, et al. Interaction between amiodarone and hepatitis-C virus nucleotide inhibitors in human induced pluripotent stem cell-derived cardiomyocytes and HEK-293 Cav1.2 over-expressing cells. Toxicol Appl Pharmacol 2016;308:66-76.https://doi.org/10.1016/j.taap.2016.08.006PMid:275207587.
7. Renet S, Chaumais MC, Antonini T, Zhao A, Thomas L, Savoure A, et al. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. Gastroenterology 2015;149(6):1378-80e1.8.
8. Ahmad T, Yin P, Saffitz J, Pockros PJ, Lalezari J, Shiffman M, et al. Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. Hepatology 2015;62(2):409-16.https://doi.org/10.1002/hep.27488PMid:252511569.
9. Zahno A, Brecht K, Morand R, Maseneni S, Torok M, Lindinger PW, et al. The role of CYP3A4 in amiodarone-associated toxicity on HepG2 cells. Biochem Pharmacol 2011;81(3):432-41.https://doi.org/10.1016/j.bcp.2010.11.002PMid:21070748
.